Journal Article
. 2012 Feb; 30(8):806-12.
doi: 10.1200/JCO.2011.37.7499.

Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer

Dawn L Hershman 1 Elizabeth T Wilde  Jason D Wright  Donna L Buono  Kevin Kalinsky  Jennifer L Malin  Alfred I Neugut  
Affiliations
  • PMID: 22312106
  •     29 References
  •     11 citations

Abstract

Purpose: In 2002, pegfilgrastim was approved by the US Food and Drug Administration and the benefits of dose-dense breast cancer chemotherapy, especially for hormone receptor (HR) -negative tumors, were reported. We examined first-cycle colony-stimulating factor use (FC-CSF) before and after 2002 and estimated US expenditures for dose-dense chemotherapy.

Methods: We identified patients in Surveillance, Epidemiology, and End Results-Medicare greater than 65 years old with stages I to III breast cancer who had greater than one chemotherapy claim within 6 months of diagnosis(1998 to 2005) and classified patients with an average cycle length less than 21 days as having received dose-dense chemotherapy. The associations of patient, tumor, and physician-related factors with the receipt of any colony-stimulating factor (CSF) and FC-CSF use were analyzed by using generalized estimating equations. CSF costs were estimated for patients who were undergoing dose-dense chemotherapy.

Results: Among the 10,773 patients identified, 5,266 patients (48.9%) had a CSF claim. CSF use was stable between 1998 and 2002 and increased from 36.8% to 73.7% between 2002 and 2005, FC-CSF use increased from 13.2% to 67.9%, and pegfilgrastim use increased from 4.1% to 83.6%. In a multivariable analysis, CSF use was associated with age and chemotherapy type and negatively associated with black/Hispanic race, rural residence, and shorter chemotherapy duration. FC-CSF use was associated with high socioeconomic status but not with age or race/ethnicity. The US annual CSF expenditure for women with HR-positive tumors treated with dose-dense chemotherapy is estimated to be $38.8 million.

Conclusion: A rapid increase in FC-CSF use occurred over a short period of time, which was likely a result of the reported benefits of dose-dense chemotherapy and the ease of pegfilgrastim administration. Because of the increasing evidence that elderly HR-positive patients do not benefit from dose-dense chemotherapy, limiting pegfilgrastim use would combat the increasing costs of cancer care.

Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer.
Dawn L Hershman, Donna Buono, +4 authors, Alfred I Neugut.
Ann Surg, 2009 Apr 24; 249(5). PMID: 19387318    Free PMC article.
Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer.
Dawn L Hershman, Donna Buono, +4 authors, Judith S Jacobson.
J Natl Cancer Inst, 2008 Jan 31; 100(3). PMID: 18230795
The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK.
Zhimei Liu, Quan V Doan, Jennifer Malin, Robert Leonard.
Appl Health Econ Health Policy, 2009 Oct 06; 7(3). PMID: 19799473
Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review.
Gary H Lyman, David C Dale, +4 authors, Jeffrey Crawford.
J Clin Oncol, 2010 Apr 14; 28(17). PMID: 20385991
Systematic Review.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Projecting future drug expenditures: 2011.
Fred Doloresco, Cory Fominaya, +5 authors, James M Hoffman.
Am J Health Syst Pharm, 2011 May 07; 68(10). PMID: 21546644
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women.
Dawn L Hershman, Donna Buono, +2 authors, Alfred I Neugut.
Cancer, 2009 Jun 12; 115(17). PMID: 19517470    Free PMC article.
Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer.
Xianglin L Du, Shenying Fang, +4 authors, Monica L Rasmus.
Cancer, 2007 Jun 22; 110(3). PMID: 17582625
Development of a comorbidity index using physician claims data.
C N Klabunde, A L Potosky, J M Legler, J L Warren.
J Clin Epidemiol, 2001 Jan 09; 53(12). PMID: 11146273
Highly Cited.
Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
F A Holmes, J A O'Shaughnessy, +10 authors, B C Liang.
J Clin Oncol, 2002 Feb 01; 20(3). PMID: 11821454
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
M D Green, H Koelbl, +12 authors, International Pegfilgrastim 749 Study Group.
Ann Oncol, 2002 Dec 19; 14(1). PMID: 12488289
Highly Cited.
Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.
J M Vose, M Crump, +8 authors, B C Liang.
J Clin Oncol, 2003 Feb 01; 21(3). PMID: 12560443
Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
E Baldini, G Gardin, +9 authors, P F Conte.
Ann Oncol, 2003 Feb 04; 14(2). PMID: 12562649
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Marc L Citron, Donald A Berry, +18 authors, Larry Norton.
J Clin Oncol, 2003 Apr 02; 21(8). PMID: 12668651
Highly Cited.
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.
Mary V Relling, James M Boyett, +7 authors, Ching-Hon Pui.
Blood, 2003 Jan 18; 101(10). PMID: 12531808
Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience.
Roy E Smith.
Clin Breast Cancer, 2003 Dec 04; 4(4). PMID: 14651772
Review.
Assessing illness severity: does clinical judgment work?
M E Charlson, F L Sax, +3 authors, R G Douglas.
J Chronic Dis, 1986 Jan 01; 39(6). PMID: 3086355
Highly Cited.
Potential for cancer related health services research using a linked Medicare-tumor registry database.
A L Potosky, G F Riley, +2 authors, L G Kessler.
Med Care, 1993 Aug 01; 31(8). PMID: 8336512
Highly Cited.
Comments on Costs of treating advanced colorectal cancer, Ross et al., Eur J Cancer 1996, 32A, S13-S17.
R Benson, C Wilson, M V Williams.
Eur J Cancer, 1998 Aug 26; 34(4). PMID: 9713318
When will the U.S. flinch at cancer drug prices?
Cori Vanchieri.
J Natl Cancer Inst, 2005 May 05; 97(9). PMID: 15870428
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
Marco Venturini, Lucia Del Mastro, +11 authors, Paolo Bruzzi.
J Natl Cancer Inst, 2005 Dec 08; 97(23). PMID: 16333028
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
Donald A Berry, Constance Cirrincione, +9 authors, Eric P Winer.
JAMA, 2006 Apr 13; 295(14). PMID: 16609087    Free PMC article.
Highly Cited.
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Thomas J Smith, James Khatcheressian, +19 authors, Antonio C Wolff.
J Clin Oncol, 2006 May 10; 24(19). PMID: 16682719
Highly Cited.
Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival.
Dawn L Hershman, Xiaoyan Wang, +3 authors, Alfred I Neugut.
Int J Radiat Oncol Biol Phys, 2006 Jun 13; 65(5). PMID: 16765531
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
M S Aapro, D A Cameron, +10 authors, European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party.
Eur J Cancer, 2006 Jun 06; 42(15). PMID: 16750358
Highly Cited. Systematic Review.
Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Dawn Hershman, Alfred I Neugut, +5 authors, Victor R Grann.
J Natl Cancer Inst, 2007 Feb 08; 99(3). PMID: 17284714
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.
Jennifer J Griggs, Eva Culakova, +5 authors, Gary H Lyman.
J Clin Oncol, 2007 Jun 20; 25(18). PMID: 17577029
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Review.
Contraindicated use of bevacizumab and toxicity in elderly patients with cancer.
Dawn L Hershman, Jason D Wright, +3 authors, Alfred I Neugut.
J Clin Oncol, 2013 Sep 05; 31(28). PMID: 24002522    Free PMC article.
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.
Didier Kamioner, Stefan Fruehauf, +3 authors, Christian Berthou.
BMC Cancer, 2013 Nov 19; 13. PMID: 24237790    Free PMC article.
Oncologists' response to new data regarding the use of epidermal growth factor receptor inhibitors in colorectal cancer.
Efrat Dotan, Tianyu Li, +3 authors, Yu-Ning Wong.
J Oncol Pract, 2014 Jul 24; 10(5). PMID: 25052499    Free PMC article.
Adjuvant Docetaxel and Cyclophosphamide (DC) with prophylactic granulocyte colony-stimulating factor (G-CSF) on days 8 &12 in breast cancer patients: a retrospective analysis.
Rinat Yerushalmi, Hadar Goldvaser, +10 authors, Salomon M Stemmer.
PLoS One, 2014 Oct 21; 9(10). PMID: 25330205    Free PMC article.
Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer.
Helen E Dinkelspiel, Ana I Tergas, +7 authors, Jason D Wright.
Gynecol Oncol, 2015 Feb 24; 137(2). PMID: 25703674    Free PMC article.
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy.
Wei Zhang, Zhiwei Jiang, +2 authors, Jielai Xia.
Med Oncol, 2015 Mar 31; 32(5). PMID: 25820754
The cost of cancer-related physician services to Medicare.
Sean Maroongroge, Simon P Kim, +6 authors, James B Yu.
Yale J Biol Med, 2015 Jun 02; 88(2). PMID: 26029009    Free PMC article.
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Jason D Wright, Ana I Tergas, +6 authors, Dawn L Hershman.
Cancer Invest, 2015 Jun 13; 33(8). PMID: 26068056    Free PMC article.
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer.
Namrata Vijayvergia, Tianyu Li, +3 authors, Efrat Dotan.
Cancer, 2016 Jul 06; 122(20). PMID: 27379436    Free PMC article.
Efficacy, safety and proper dose analysis of PEGylated granulocyte colony-stimulating factor as support for dose-dense adjuvant chemotherapy in node positive Chinese breast cancer patients.
Fan Zhang, RuiXia LingHu, +5 authors, Junlan Yang.
Oncotarget, 2017 Nov 08; 8(45). PMID: 29108384    Free PMC article.